Integra Therapeutics at ‘CRISPR News Medicine’
CRISPR News Medicine publishes an article entitled Adaptation of jumping gene boosts CRISPR-Cas gene-writing technology to new heights about new FiCAT platform developed by Integra Therapeutics. By Henri van de Vrugt
Integra Therapeutics at ‘Pharmaceutical Technology’
Pharmaceutical Technology review publishes an article entitled Integra Therapeutics Q&A: building next-generation gene editing tools where our CEO Avencia Sánchez-Mejías discusses how the company’s gene writing tool could improve advanced therapies for patients. By Darcy Jimenez
‘Nature Communications’ publishes new gene writing technology to allow for more effective and safe advanced therapies
Developed by researchers at the Translational Synthetic Biology Lab at the Pompeu Fabra University (UPF) led by Dr Marc Güell. UPF has transferred the technology to Integra Tx.
Integra Therapeutics secures €4.5-million in funding from Advent France Biotechnology, Invivo Capital and Takeda Ventures
The investment will be used to develop an innovative gene writing platform with the potential to make advanced therapies safer and more effective.